TOVX
Theriva Biologics, Inc.
stockNYSEAMERICAN
synthetic biologics, inc. (nyse mkt: syn) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. the company's lead candidates poised for phase 3 development are: (1) syn-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (ibs-c), and (2) syn-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (iv) beta-lactam antibiotics for the prevention of c. difficile infection (cdi), antibiotic-associated diarrhea (aad) and the emergence of antimicrobial-resistance (amr). the company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (pku).
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.22 | 2026-09-28 | +9.93% | -2.452 |
| 1M | 0.25 | 2026-09-04 | -5.93% | 1.502 |
| 3M | 0.25 | 2026-07-06 | -6.04% | 1.012 |
| 6M | 0.25 | 2026-04-06 | -4.22% | 2.512 |
| 1Y | 0.42 | 2025-10-03 | -42.73% | 2.762 |
| 2Y | 1.68 | 2024-10-04 | -85.83% | — |
| 5Y | 25.76 | 2022-10-13 | -99.08% | 0.882 |
Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) stock price today is $0.24, and today's volume is 399,099. TOVX is up 5.778% today. The 30 day average volume is 495,067. TOVX market cap is $10.92M with 45.89M shares outstanding.